Teams mobilized to meet the needs of hospitals.
All over the world, Air Liquide has stepped up in the face of the pandemic by supplying the medical oxygen needed to combat Covid-19. Our employees raced against the clock to offer help to caregivers by increasing production and adjusting the supply chain. In the hardest-hit areas, hospital demand for oxygen increased sixfold and even tenfold.
Contributing to global efforts to fight Covid-19 by opening access to a new adjuvant that increases the efficacy of vaccines.
Furthering vaccine research is one of our ambitions. Seppic, an Air Liquide subsidiary that manufactures specialty ingredients, stepped up in the face of the pandemic by making its Sepivac SWE™ adjuvant-which was developed in partnership with the Vaccine Formulation Institute(1) -available to the global scientific community. Available without a license, this adjuvant helps accelerate the development of vaccines to combat influenza and Covid-19.